Skip to main content

Caprion Identifies Protein Biomarkers for Predicting Patient Response to New Hepatitis C Drug


Caprion Proteomics announced this week that it has identified a panel of protein biomarkers that could be useful in predicting patient response to a new treatment for hepatitis C.

The company said that the biomarkers were correlated with sustained viral response or viral cure in response to a combined treatment of pegylated-interferon, ribavirin, and telaprevir, a drug candidate for hepatitis C.

The study was part of a collaboration between Caprion and Vertex Pharmaceuticals, the maker of telaprevir. Caprion used its s mass spectrometry-based proteomics platform CellCarta to discover the markers by comparing the expression levels of thousands of proteins in blood samples from hepatitis C patients.

The study also suggested potential differences within the segments of the hepatitis C patient population that could be used for stratification and tailoring individual therapies, Caprion said.

Research on the biomarkers in larger patient populations is currently underway, and the company plans to perform further validation assays on the panel using its multiple-reaction monitoring mass spec platform.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.